These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36705799)

  • 1. The Influence of the FFAR4 Agonist TUG-891 on Liver Steatosis in ApoE-Knockout Mice.
    Kiepura A; Suski M; Stachyra K; Kuś K; Czepiel K; Wiśniewska A; Ulatowska-Białas M; Olszanecki R
    Cardiovasc Drugs Ther; 2024 Aug; 38(4):667-678. PubMed ID: 36705799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Anti-Atherosclerotic Action of FFAR4 Agonist TUG-891 in ApoE-Knockout Mice Is Associated with Increased Macrophage Polarization towards M2 Phenotype.
    Kiepura A; Stachyra K; Wiśniewska A; Kuś K; Czepiel K; Suski M; Ulatowska-Białas M; Surmiak M; Olszanecki R
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575934
    [No Abstract]   [Full Text] [Related]  

  • 3. DHA supplementation prevent the progression of NASH via GPR120 signaling.
    Nakamoto K; Shimada K; Harada S; Morimoto Y; Hirasawa A; Tokuyama S
    Eur J Pharmacol; 2018 Feb; 820():31-38. PubMed ID: 29221950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Involvement of the Free Fatty Acid Receptor GPR120/FFAR4 in the Development of Nonalcoholic Steatohepatitis].
    Nakamoto K; Tokuyama S
    Yakugaku Zasshi; 2019; 139(9):1169-1175. PubMed ID: 31474633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ferulic acid ameliorates nonalcoholic fatty liver disease and modulates the gut microbiota composition in high-fat diet fed ApoE
    Ma Y; Chen K; Lv L; Wu S; Guo Z
    Biomed Pharmacother; 2019 May; 113():108753. PubMed ID: 30856537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docosahexaenoic Acid Attenuates the Progression of Nonalcoholic Steatohepatitis by Suppressing the Adipocyte Inflammation via the G Protein-Coupled Receptor 120/Free Fatty Acid Receptor 4 Pathway.
    Nakamoto K; Tokuyama S
    Pharmacology; 2022; 107(5-6):330-338. PubMed ID: 35189618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).
    Wang Z; Li S; Wang R; Guo L; Xu D; Zhang T; Xu Y; Wang W; Wang M; Gan Z; Wang X
    Mol Med; 2020 Jun; 26(1):54. PubMed ID: 32503411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of non-alcoholic fatty liver disease by targeting adhesion G protein-coupled receptor F1 (
    Wu M; Lo TH; Li L; Sun J; Deng C; Chan KY; Li X; Yeh ST; Lee JTH; Lui PPY; Xu A; Wong CM
    Elife; 2023 Aug; 12():. PubMed ID: 37580962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Atherosclerosis and Liver Steatosis by Agmatine in Western Diet-Fed apoE-Knockout Mice Is Associated with Decrease in Hepatic De Novo Lipogenesis and Reduction in Plasma Triglyceride/High-Density Lipoprotein Cholesterol Ratio.
    Wiśniewska A; Stachowicz A; Kuś K; Ulatowska-Białas M; Totoń-Żurańska J; Kiepura A; Stachyra K; Suski M; Gajda M; Jawień J; Olszanecki R
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous
    Jiang X; Yang Q; Qu H; Chen Y; Zhu S
    Nutrients; 2023 Jan; 15(3):. PubMed ID: 36771292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theobromine ameliorates nonalcoholic fatty liver disease by regulating hepatic lipid metabolism via mTOR signaling pathway in vivo and in vitro.
    Wei D; Wu S; Liu J; Zhang X; Guan X; Gao L; Xu Z
    Can J Physiol Pharmacol; 2021 Aug; 99(8):775-785. PubMed ID: 33290156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPR40 deficiency is associated with hepatic FAT/CD36 upregulation, steatosis, inflammation, and cell injury in C57BL/6 mice.
    Lu Z; Li Y; Syn WK; Li AJ; Ritter WS; Wank SA; Lopes-Virella MF; Huang Y
    Am J Physiol Endocrinol Metab; 2021 Jan; 320(1):E30-E42. PubMed ID: 33103454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
    Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
    Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodesoxycholic acid is an FFA4 agonist and reduces hepatic steatosis via FFA4 signaling.
    Xu F; Wang J; Wang P; Hou T; Zhou H; Zhao Y; Wang J; Liu Y; Liang X
    Eur J Pharmacol; 2022 Feb; 917():174760. PubMed ID: 35033554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-hepatic steatosis activity of Sicyos angulatus extract in high-fat diet-fed mice and chemical profiling study using UHPLC-qTOF-MS/MS spectrometry.
    An JP; Choi JH; Huh J; Lee HJ; Han S; Noh JR; Kim YH; Lee CH; Oh WK
    Phytomedicine; 2019 Oct; 63():152999. PubMed ID: 31280138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
    Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
    Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice.
    Kant R; Lu CK; Nguyen HM; Hsiao HH; Chen CJ; Hsiao HP; Lin KJ; Fang CC; Yen CH
    Biomed Pharmacother; 2020 Sep; 129():110348. PubMed ID: 32554245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE
    Nasiri-Ansari N; Nikolopoulou C; Papoutsi K; Kyrou I; Mantzoros CS; Kyriakopoulos G; Chatzigeorgiou A; Kalotychou V; Randeva MS; Chatha K; Kontzoglou K; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
    Hong Y; Choi SI; Hong E; Kim GH
    J Food Sci; 2020 Jul; 85(7):2216-2226. PubMed ID: 32579753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
    Yin X; Liu Z; Wang J
    Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.